[Second-line eradication therapy for H. pylori infection]

Area of Science:

• Microbiology
• Pharmacology
• Gastroenterology

Background:

• Widespread Helicobacter pylori eradication therapy has increased antibiotic-resistant strains.
• Treatment failure necessitates retreatment, with varying global and institutional policies.
• Bismuth and tetracycline regimens are effective for retreatment worldwide, but not standardized in Japan.

Purpose of the Study:

• To address the lack of consensus on Helicobacter pylori retreatment in Japan.
• To evaluate the efficacy of second-line therapies for H. pylori eradication failure.
• To highlight the regulatory challenges of using metronidazole in Japan.

Main Methods:

• Review of existing literature on H. pylori retreatment regimens.
• Analysis of reported cure rates for different therapeutic approaches.
• Comparison of international practices with Japanese institutional policies.

Main Results:

• Bismuth and tetracycline-containing regimens demonstrate good retreatment success globally.
• Triple therapy with proton pump inhibitor, amoxicillin, and metronidazole shows potential in Japan.
• Metronidazole, despite global use, lacks regulatory approval for H. pylori in Japan.

Conclusions:

• Standardized retreatment guidelines for H. pylori are needed in Japan.
• Further investigation into metronidazole's efficacy and safety for H. pylori in Japan is warranted.
• International successful retreatment strategies may offer valuable insights for Japan.